Latest News

Editorial: A proposal to correct minority underrepresentation in clinical trials

In an editorial published in CNS Spectrums, Jay Avasarala, MD, Ph.D., takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).

Source link

Related posts

Essential Oils Promise Help, But Beware the Risks


Scientists develop new approach to unravel toxic effects of multiple stressors


Celiac disease may now be curable with biodegradable nanoparticles


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy